{"id":63250,"date":"2026-04-15T22:12:29","date_gmt":"2026-04-15T14:12:29","guid":{"rendered":"https:\/\/flcube.com\/?p=63250"},"modified":"2026-04-15T22:12:30","modified_gmt":"2026-04-15T14:12:30","slug":"ac-immune-and-eli-lilly-amend-2018-alzheimers-partnership-to-advance-tau-morphomer-candidates","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63250","title":{"rendered":"AC Immune and Eli Lilly Amend 2018 Alzheimer&#8217;s Partnership to Advance Tau Morphomer Candidates"},"content":{"rendered":"\n<p><strong>AC Immune SA<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/ACIU:NASDAQ\">NASDAQ: ACIU<\/a>) and <strong>Eli Lilly and Company<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/LLY:NYSE\">NYSE: LLY<\/a>) announced a <strong>revised licensing agreement<\/strong> amending their original 2018 partnership, refocusing efforts on the development of <strong>small-molecule tau protein aggregation inhibitors<\/strong> for <strong>Alzheimer&#8217;s disease (AD)<\/strong> and other neurodegenerative disorders, with emphasis on advancing a lead <strong>Tau Morphomer candidate compound<\/strong> and potential backup molecules.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-amendment-overview\">Partnership Amendment Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Original Agreement<\/strong><\/td><td>2018 licensing partnership<\/td><\/tr><tr><td><strong>Parties<\/strong><\/td><td>AC Immune SA (NASDAQ: ACIU) and Eli Lilly (NYSE: LLY)<\/td><\/tr><tr><td><strong>Therapeutic Focus<\/strong><\/td><td>Small-molecule tau protein aggregation inhibitors<\/td><\/tr><tr><td><strong>Indications<\/strong><\/td><td>Alzheimer&#8217;s disease and other neurodegenerative diseases<\/td><\/tr><tr><td><strong>Lead Asset<\/strong><\/td><td>Tau Morphomer candidate compound plus backup candidates<\/td><\/tr><tr><td><strong>Upfront Payment<\/strong><\/td><td>CHF 10 million to AC Immune<\/td><\/tr><tr><td><strong>Next Milestone<\/strong><\/td><td>First patient dosed in Phase I clinical trial<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-terms-amp-milestone-structure\">Financial Terms &amp; Milestone Structure<\/h2>\n\n\n\n<p>The amended agreement maintains AC Immune&#8217;s substantial long-term financial upside while providing immediate funding for continued development:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Immediate Payment<\/strong>: CHF 10 million upfront payment to AC Immune<\/li>\n\n\n\n<li><strong>Near-Term Milestone<\/strong>: Additional payment upon first patient dosing in Phase I trial<\/li>\n\n\n\n<li><strong>Total Potential Value<\/strong>: Over <strong>CHF 1.7 billion<\/strong> in subsequent development, regulatory, and commercial milestones<\/li>\n\n\n\n<li><strong>Royalty Structure<\/strong>: Low-double-digit tiered royalties on net sales<\/li>\n\n\n\n<li><strong>Exclusions<\/strong>: New milestone payments are separate from previously announced amendment milestones<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-scientific-rationale-amp-therapeutic-approach\">Scientific Rationale &amp; Therapeutic Approach<\/h2>\n\n\n\n<p><strong>Tau protein aggregation<\/strong> represents a critical pathological hallmark of Alzheimer&#8217;s disease and related tauopathies:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target Mechanism<\/strong>: Small-molecule inhibition of tau protein misfolding and aggregation<\/li>\n\n\n\n<li><strong>Technology Platform<\/strong>: AC Immune&#8217;s proprietary <strong>Tau Morphomer<\/strong> technology<\/li>\n\n\n\n<li><strong>Therapeutic Rationale<\/strong>: Addressing tau pathology may provide disease-modifying effects beyond symptomatic treatment<\/li>\n\n\n\n<li><strong>Development Stage<\/strong>: Preclinical advancement toward Phase I clinical trials<\/li>\n<\/ul>\n\n\n\n<p>The focus on <strong>small-molecule approaches<\/strong> differentiates this program from antibody-based tau therapies, potentially offering advantages in blood-brain barrier penetration, oral bioavailability, and manufacturing scalability.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-for-ac-immune\">For AC Immune<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pipeline Validation<\/strong>: Continued Lilly partnership validates Tau Morphomer platform technology<\/li>\n\n\n\n<li><strong>Financial Stability<\/strong>: Upfront payment supports ongoing operations and pipeline development<\/li>\n\n\n\n<li><strong>Risk Mitigation<\/strong>: Partnership structure reduces development burden while maintaining significant upside<\/li>\n\n\n\n<li><strong>Focus Optimization<\/strong>: Enables concentration on core tau and amyloid programs<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-for-eli-lilly\">For Eli Lilly<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Portfolio Diversification<\/strong>: Expands Alzheimer&#8217;s pipeline beyond current amyloid-focused approaches<\/li>\n\n\n\n<li><strong>Scientific Access<\/strong>: Gains access to AC Immune&#8217;s specialized tau expertise and proprietary compounds<\/li>\n\n\n\n<li><strong>Competitive Positioning<\/strong>: Strengthens position in next-generation Alzheimer&#8217;s therapeutics<\/li>\n\n\n\n<li><strong>Risk Management<\/strong>: Balanced investment approach with milestone-based payments<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<p>The <strong>Alzheimer&#8217;s disease therapeutics market<\/strong> is experiencing renewed interest following recent regulatory approvals of disease-modifying therapies targeting amyloid pathology. However, significant unmet need remains for treatments addressing <strong>tau pathology<\/strong>, which correlates more closely with cognitive decline and disease progression.<\/p>\n\n\n\n<p>AC Immune&#8217;s <strong>Tau Morphomer<\/strong> approach represents one of several emerging strategies to target tau aggregation, positioning the company at the forefront of next-generation Alzheimer&#8217;s research alongside established players like Lilly.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-industry-outlook\">Industry Outlook<\/h2>\n\n\n\n<p>This partnership amendment reflects the <strong>evolving Alzheimer&#8217;s therapeutic landscape<\/strong>, where combination approaches targeting multiple pathological pathways (amyloid + tau) may ultimately prove most effective. The continued collaboration between AC Immune and Lilly demonstrates confidence in tau-targeting strategies despite historical challenges in neurodegenerative drug development.<\/p>\n\n\n\n<p>The substantial milestone structure (CHF 1.7+ billion) indicates Lilly&#8217;s commitment to potentially transformative Alzheimer&#8217;s therapies, while the small-molecule focus addresses delivery and manufacturability challenges that have limited previous tau-targeting approaches.<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding partnership amendments, clinical development timelines, regulatory approvals, and financial milestones for tau-targeting Alzheimer&#8217;s therapies. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive developments, and the inherent challenges of neurodegenerative disease drug development.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AC Immune SA (NASDAQ: ACIU) and Eli Lilly and Company (NYSE: LLY) announced a revised&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[795,199,4693,911],"class_list":["post-63250","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-ac-immune","tag-eli-lilly","tag-nasdaq-aciu","tag-nyse-lly"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AC Immune and Eli Lilly Amend 2018 Alzheimer&#039;s Partnership to Advance Tau Morphomer Candidates - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"AC Immune SA (NASDAQ: ACIU) and Eli Lilly and Company (NYSE: LLY) announced a revised licensing agreement amending their original 2018 partnership, refocusing efforts on the development of small-molecule tau protein aggregation inhibitors for Alzheimer&#039;s disease (AD) and other neurodegenerative disorders, with emphasis on advancing a lead Tau Morphomer candidate compound and potential backup molecules.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63250\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AC Immune and Eli Lilly Amend 2018 Alzheimer&#039;s Partnership to Advance Tau Morphomer Candidates\" \/>\n<meta property=\"og:description\" content=\"AC Immune SA (NASDAQ: ACIU) and Eli Lilly and Company (NYSE: LLY) announced a revised licensing agreement amending their original 2018 partnership, refocusing efforts on the development of small-molecule tau protein aggregation inhibitors for Alzheimer&#039;s disease (AD) and other neurodegenerative disorders, with emphasis on advancing a lead Tau Morphomer candidate compound and potential backup molecules.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63250\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-15T14:12:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-15T14:12:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63250#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63250\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AC Immune and Eli Lilly Amend 2018 Alzheimer&#8217;s Partnership to Advance Tau Morphomer Candidates\",\"datePublished\":\"2026-04-15T14:12:29+00:00\",\"dateModified\":\"2026-04-15T14:12:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63250\"},\"wordCount\":582,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AC Immune\",\"Eli Lilly\",\"NASDAQ: ACIU\",\"NYSE: LLY\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63250#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63250\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63250\",\"name\":\"AC Immune and Eli Lilly Amend 2018 Alzheimer's Partnership to Advance Tau Morphomer Candidates - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-15T14:12:29+00:00\",\"dateModified\":\"2026-04-15T14:12:30+00:00\",\"description\":\"AC Immune SA (NASDAQ: ACIU) and Eli Lilly and Company (NYSE: LLY) announced a revised licensing agreement amending their original 2018 partnership, refocusing efforts on the development of small-molecule tau protein aggregation inhibitors for Alzheimer's disease (AD) and other neurodegenerative disorders, with emphasis on advancing a lead Tau Morphomer candidate compound and potential backup molecules.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63250#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63250\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63250#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AC Immune and Eli Lilly Amend 2018 Alzheimer&#8217;s Partnership to Advance Tau Morphomer Candidates\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AC Immune and Eli Lilly Amend 2018 Alzheimer's Partnership to Advance Tau Morphomer Candidates - Insight, China&#039;s Pharmaceutical Industry","description":"AC Immune SA (NASDAQ: ACIU) and Eli Lilly and Company (NYSE: LLY) announced a revised licensing agreement amending their original 2018 partnership, refocusing efforts on the development of small-molecule tau protein aggregation inhibitors for Alzheimer's disease (AD) and other neurodegenerative disorders, with emphasis on advancing a lead Tau Morphomer candidate compound and potential backup molecules.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63250","og_locale":"en_US","og_type":"article","og_title":"AC Immune and Eli Lilly Amend 2018 Alzheimer's Partnership to Advance Tau Morphomer Candidates","og_description":"AC Immune SA (NASDAQ: ACIU) and Eli Lilly and Company (NYSE: LLY) announced a revised licensing agreement amending their original 2018 partnership, refocusing efforts on the development of small-molecule tau protein aggregation inhibitors for Alzheimer's disease (AD) and other neurodegenerative disorders, with emphasis on advancing a lead Tau Morphomer candidate compound and potential backup molecules.","og_url":"https:\/\/flcube.com\/?p=63250","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-15T14:12:29+00:00","article_modified_time":"2026-04-15T14:12:30+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63250#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63250"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AC Immune and Eli Lilly Amend 2018 Alzheimer&#8217;s Partnership to Advance Tau Morphomer Candidates","datePublished":"2026-04-15T14:12:29+00:00","dateModified":"2026-04-15T14:12:30+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63250"},"wordCount":582,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AC Immune","Eli Lilly","NASDAQ: ACIU","NYSE: LLY"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63250#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63250","url":"https:\/\/flcube.com\/?p=63250","name":"AC Immune and Eli Lilly Amend 2018 Alzheimer's Partnership to Advance Tau Morphomer Candidates - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-15T14:12:29+00:00","dateModified":"2026-04-15T14:12:30+00:00","description":"AC Immune SA (NASDAQ: ACIU) and Eli Lilly and Company (NYSE: LLY) announced a revised licensing agreement amending their original 2018 partnership, refocusing efforts on the development of small-molecule tau protein aggregation inhibitors for Alzheimer's disease (AD) and other neurodegenerative disorders, with emphasis on advancing a lead Tau Morphomer candidate compound and potential backup molecules.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63250#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63250"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63250#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AC Immune and Eli Lilly Amend 2018 Alzheimer&#8217;s Partnership to Advance Tau Morphomer Candidates"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63250","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63250"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63250\/revisions"}],"predecessor-version":[{"id":63251,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63250\/revisions\/63251"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63250"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63250"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63250"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}